



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

TICKLE, et al.

Atty. Ref.: 620-282

Serial No. 10/690,991

Group:

Filed: October 23, 2003

Examiner:

For: CRYSTAL STRUCTURE OF CYTOCHROME P450

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

March 5, 2004

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

TICKLE, et al.
Serial No. 10/690,991

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: _____



B. J. Sadoff
Reg. No. 36,663

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100


**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

620-282

APPLICANT

TICKLE, et al.

FILING DATE

October 23, 2003

SERIAL NO.

10/690,991

(Use several sheets if necessary)

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,786,191	07/28/98	Goldstein et al			
	5,912,120	06/15/99	Goldstein et al			
	5,834,250	11/10/98	Wells et al			
	6,080,568	06/27/00	Day et al			
	6,136,553	10/24/00	Christianson et al			
	6,162,613	12/19/00	Su et al			
	5,886,157	03/23/99	Guengerich et al			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
WO 98/02554	01/22/98	WIPO			
WO 01/14565	03/01/01	WIPO			
WO 01/11035	02/15/01	WIPO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Abstract 4, Abstracts from 8 th European ISSX Meeting (Monday 28 th April 2003), Structural Characterisation of Substrate and Inhibitor Binding to 2C P450s, Eric Johnson, Scripps Research Institute, La Jolla, CA, USA
	Wester et al, Structure of a Substrate Complex of Mammalian Cytochrome P450 2C5 at 2.3 Å Resolution: Evidence of Multiple Substrate Binding Modes, <i>Biochemistry</i> 2003, 42, 6370-6379
	Wester et al, Structure of Mammalian Cytochrome P450 2C5 Complexed with Diclofenac at 2.1 Å Resolution: Evidence for an Induced Fit Model of Substrate Binding, <i>Biochemistry</i> 2003, 42, 9335-9345
	Crystal Structure of human cytochrome P450 2C9 with bound warfarin; Williams, P.A.; Cosme, J.; Ward, A.; Angrove, H.C.; Matak-Vinkovic, D.; Jhoti, H.; <i>Nature</i> , 2003, Jul 24; 424(6947): 464-8. (Published online Jul 13 2003).
	IF Sevrioukova, H Li, H Zhang, JA Peterson, TL Poulos, Structure of a cytochrome P450-redox partner electron-transfer complex. <i>Proceedings of the National Academy of Sciences of the United States of America</i> (1999) 96, pp. 1863-8
	Szklarz GD, Halpert JR.; Molecular modeling of cytochrome P450 3A4; <i>J. Comput. Aided Mol. Des.</i> ; 1997;11(3); 265-72.
	Lewis DF, Eddershaw PJ, Goldfarb PS, Tarbit MH.; Molecular modelling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A-specific chemicals; <i>Xenobiotica</i> ; 1996; 26(10);1067-86.
	Guengerich FP; Cytochrome P-450 3A4: regulation and role in drug metabolism; <i>Annu. Rev. Pharmacol. Toxicol.</i> ; 1999; 39;1-17.
	Ekins S, Bravi G, Wikel JH, Wrighton SA.; Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates; <i>J Pharmacol Exp Ther.</i> ; 1999; 291(1); 424-33.
	Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, Wrighton SA.; Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors; <i>J Pharmacol Exp Ther.</i> ; 1999; 290(1); 429-38.

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-282

10/690,991

APPLICANT

TICKLE, et al.

(Use several sheets if necessary)

FILING DATE

GROUP

October 23, 2003

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Gonzalez, F.J., Schmid, B.J., Umeno, M., McBride, O.W., Hardwick, J.P., Meyer, U.A., Gelboin, H.V. and Idle, J.R., Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase, <i>DNA</i> 7 (2), 79-86 (1988).
	Beaune, P.H., Umbenhauer, D.R., Bork, R.W., Lloyd, R.S. and Guengerich, F.P., Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase, <i>Proc. Natl. Acad. Sci. U.S.A.</i> ; 83 (21), 8064-8068 (1986).
	Korzekwa, K.R.; Krishnamachary, N.; Shou, M.; Ogai, A.; Parise, R.A.; Rettie, A.E.; Gonzalez, F.J.; Tracey, T.S.; Evaluation Of Atypical Cytochrome P450 Kinetics With Two-Substrate Models: Evidence That Multiple Substrate Can Bind Simultaneously Bind To Cytochrome P450 Active Sites; <i>Biochemistry</i> ; 1998, Vol 37, 4137-4147.
	Hosea NA, Miller GP, Guengerich FP.; Elucidation of distinct ligand binding sites for cytochrome P450 3A4; <i>Biochemistry</i> ; 2000; 39(20), 5929-39.
	Williams, P.; Cosme, J.; Sridhar, V.; Johnson, E. and McRee, D.; Microsomal cytochrome P450 2C5: comparison of microbial P450s and unique features, <i>Journal of Inorganic Biochemistry</i> , 2000, Vol. 81, pp183-190.
	T. H. Richardson, F. Jung, K. J. Griffin, M. Wester, J. L. Raucy, B. Kemper, L. M. Bornheim, C. Hassett, C. J. Omiecinski and E. F. Johnson; A Universal Approach to the Expression of Human and Rabbit Cytochrome P450s of the 2C Subfamily in Escherichia coli; <i>Archives of Biochemistry and Biophysics</i> , 1995, Volume 323, 87-96.
	JP10033166A2; Mass Expression System Of Modified Substance Of Ctochrome P450 2c19 In Escherichia Coli; Inventor: Baba Takahiko; Kirita Shiro; Aoyama Junko; Assignee: Shionogi & Co Ltd; Filed: July 23, 1996. (with English abstract.)
	Barnes HJ, Arlotto MP, Waterman MR; Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in Escherichia coli; <i>Proc. Natl. acad. Sci. USA</i> ; 1991, 88, 5597-5601.
	Kempf AC, Zanger UM, Meyer UA; Truncated human P450 2D6: expression in Escherichia coli, Ni(2+)-chelate affinity purification, and characterization of solubility and aggregation; <i>Arch. Biochem. Biophys.</i> , 1995, 321, 277-288.
	Gillam EM, Guo Z, Martin MV, Jenkins CM, Guengerich FP; Expression of cytochrome P450 2D6 in Escherichia coli, purification, and spectral and catalytic characterization; <i>Arch. Biochem. Biophys.</i> , 1995, 319, 540-550.
	Pernecky SJ, Larson JR, Philpot RM, Coon MJ; Expression of truncated forms of liver microsomal P450 cytochromes 2B4 and 2E1 in Escherichia coli: influence of NH2-terminal region on localization in cytosol and membranes; <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90, 2651-2655.

*Examiner	Date Considered
-----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-282

10/690,991

APPLICANT

TICKLE, et al.

(Use several sheets if necessary)

FILING DATE

GROUP

October 23, 2003

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	JR Larson, MJ Coon, and TD Porter; Alcohol-inducible cytochrome P-450IIE1 lacking the hydrophobic NH ₂ -terminal segment retains catalytic activity and is membrane-bound when expressed in <i>Escherichia coli</i> ; <i>J. Biol. Chem.</i> , 1991 , 266, 7321-7324.
	Sagara Y., Barnes H. J. and Waterman M. R.; Expression in <i>Escherichia coli</i> of Functional Cytochrome P450 _{c17} Lacking Its Hydrophobic Amino-Terminal Signal Anchor, <i>Arch. Biochem. Biophys.</i> , 1993 , 304, 272-278.
	Emily E. Scott, Margit Spatzenegger and James R. Halpert ; A Truncation of 2B Subfamily Cytochromes P450 Yields Increased Expression Levels, Increased Solubility, and Decreased Aggregation While Retaining Function, <i>Arch. Biochem. Biophys.</i> , 2001 , Volume 395, Issue 1, 57-68.
	Gillam EM, Baba T, Kim BR, Ohmori S, Guengerich FP; Expression of modified human cytochrome P450 3A4 in <i>Escherichia coli</i> and purification and reconstitution of the enzyme; <i>Arch Biochem Biophys.</i> , 1993 ; 305(1); 123-31.
	Meehan,R.R., Gosden,J.R., Rout,D., Hastie,N.D., Friedberg,T., Adesnik,M., Buckland,R., van Heyningen,V., Fletcher,J.M., Spurr,N.K., Sweeney,J. and Wolf,C.R.; Human cytochrome P-450 PB-1: a multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10; <i>Am. J. Hum. Genet.</i> ; 1988 , 42 (1), 26-37.
	Kimura,S., Pastewka,J., Gelboin,H.V. and Gonzalez,F.J.; cDNA and amino acid sequences of two members of the human P450IIC gene subfamily; <i>Nucleic Acids Res.</i> ; 1987 , 15 (23), 10053-10054.
	Romkes,M., Falletto,M.B., Blaisdell,J.A., Raucy,J.L. and Goldstein,J.A.; Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily; <i>Biochemistry</i> ; 1991 , 30 (13), 3247-3255.
	Gonzalez,F.J., Vilbois,F., Hardwick,J.P., McBride,O.W., Nebert,D.W., Gelboin,H.V. and Meyer,U.A.; Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22; <i>Genomics</i> , 1988 , vol 2 (2), 174-179.
	David R. Nelson <i>et al.</i> , P450 Superfamily: update on new sequences, gene mapping, accession numbers and nomenclature, <i>Pharmacogenetics</i> 6 1-42 (1996).
	Nienaber <i>et al.</i> , Re-engineering of Human Urokinase Provides a System for Structure-based Drug Design at High Resolution and Reveals a Novel Structural Subsite, <i>J. Biol. Chem.</i> 275 (10) 7239-7248 (2000)
	Dale <i>et al.</i> , Crystal Engineering: deletion mutagenesis of the 24 kDa fragment of the DNA gyrase B subunit from <i>Staphylococcus aureus</i> , <i>Acta Crystallographica</i> D55 , 1626-1629 (1999)

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-282

10/690,991

APPLICANT

TICKLE, et al.

(Use several sheets if necessary)

FILING DATE

GROUP

October 23, 2003

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Wolfram Schiweck and Arne Skerra, The Rational Construction of an Antibody against Cystatin: Lessons from the crystal structure of an artificial Fab fragment, <i>J. Mol. Biol.</i> 268 934-951 (1997)
	Stephen R. Price and Kiyoshi Nagai, Protein Engineering as a Tool for Crystallography, <i>Current Opinion in Biotechnology</i> 6 425-430 (1995)
	Lawson <i>et al.</i> , Solving the Structure of Human H Ferritin by Genetically Engineering Intermolecular Crystal Contacts, <i>Nature</i> 349 541-544 (1991)
	Park Sam-Yong et al, Crystallization and Preliminary X-ray Diffraction Analysis of a Cytochrome P450 (CYP119) from <i>Sulfolobus solfataricus</i> , <i>Acta Crystallographica Section D Biological Crystallography</i> 56 : 1173-1175, 2000
	Ridderstrom et al, Arginines 97 and 108 in CYP2C9 Are Important Determinants of the Catalytic Function, <i>Biochemical and Biophysical Research Communications</i> 270 : 983-987, 2000
	Payne et al, Homology Modeling and Substrate Binding Study of Human CYP2C9 Enzyme, <i>Proteins</i> , 37 : 176-190, 1999
	Ekins et al, Pharmacophore and Three-Dimensional Quantitative Structure Activity Relationship Methods For Modeling Cytochrome P450 Active Sites, <i>Drug Metabolism and Disposition</i> , 29 : 936-944, 2001
	Stubbins et al, Genetic Analysis of the Human Cytochrome P450 CYP2C9 Locus, <i>Pharmacogenetics</i> , 6 : 429-439, 1996.

*Examiner	Date Considered
-----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)